1. Home
  2. Category
  3. Professional Issues

Genetics and Genomics

Letter

Considerations for the Telephone Disclosure of Genetic Test Results to Patients With Cancer

Suzanne M. Mahon
CJON 2020, 24(1), 8 DOI: 10.1188/20.CJON.8
I would like to thank Cantril, Moore, and Yan (2019) for their informative article on patient preferences for the disclosure of a breast cancer diagnosis in the December issue of the Clinical Journal of Oncology Nursing . The findings of Cantril et al.’s (2019) study suggest that patients prefer in...
0
No votes yet
Read this Article
Genetics & Genomics

Liquid Biopsy: A Tool for the Diagnostic and Prognostic Evaluation of Cancers

Joshua Stanciu
Joseph D. Tariman
CJON 2020, 24(1), 19-21 DOI: 10.1188/20.CJON.19-21
Liquid biopsy is defined as the process of obtaining material for pathologic examination and analysis from body fluids. Liquid biopsy has been intensively researched for its clinical application in patients with solid malignancies, including melanoma and colon, breast, and lung cancers. This will...
0
No votes yet
Read this Article
Online Exclusive Article

Mental Illness and BRCA1/2 Genetic Testing Intention Among Multiethnic Women Undergoing Screening Mammography

Tarsha Jones
Katherine Freeman
Marra Ackerman
Meghna S. Trivedi
Thomas Silverman
Peter Shapiro
Rita Kukafka
Katherine D. Crew
ONF 2020, 47(1), E13-E24 DOI: 10.1188/20.ONF.E13-E24
Objectives: To examine associations between patient-reported mental illness diagnosis and symptoms and BRCA1/2 genetic testing intention among women undergoing screening mammography. Sample & Setting: 100 multiethnic women of lower socioeconomic status who were undergoing mammography screening...
0
No votes yet
Read this Article
Genetics and Genomics

Hereditary Pancreatic Cancer Syndromes: Providing Care to At-Risk Families

Elisabeth King
Bita M. Nehoray
CJON 2019, 23(6), 579-582 DOI: 10.1188/19.CJON.579-582
Hereditary pancreatic cancer continues to pose challenges to providers, as well as to patients and their families. Pancreatic cancer has a poor prognosis, and individuals with family histories of pancreatic cancer are often motivated to pursue genetic testing. This article reviews various...
0
No votes yet
Read this Article
Article

Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation–Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis

Ilene Galinsky
Melanie Coleman
Lenn Fechter
CJON 2019, 23(6), 599-608 DOI: 10.1188/19.CJON.599-608
Background: Acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM) are clonal diseases of the blood. Prognoses for patients with FMS-like tyrosine kinase 3 ( FLT3 ) mutation–positive AML and those with advanced SM are poor. In the United States, midostaurin was approved in 2017 in...
0
No votes yet
Read this Article

Related e-Books

View More

Questions, Concerns or Requests

We're just a click away for assistance.